Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608177 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02608177 is a NA study that has completed, run by University of Washington. The registered enrollment target is 3 participants.
The verdict
NCT02608177, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
Interventions
- DRUG Glipizide
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608177
The ClinicalTrials.gov registry entry for NCT02608177 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glipizide is the first listed.
NCT02608177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608177 about?
NCT02608177 is a clinical study titled "Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management". The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
What is the current status of trial NCT02608177?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2015-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02608177?
The interventions under investigation include: Glipizide (DRUG), Linagliptin (DRUG).
Who is sponsoring clinical trial NCT02608177?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.